Floatz logo

(1R,3S,4R)-4-((3AR,9BR)-9B-((4-FLUOROPHENYL)SULFONYL)-7-(PERFLUOROPROPAN-2-YL)-2,3,3A,4,5,9B-HEXAHYDRO-1H-BENZO(E)INDOLE-3-CARBONYL)-3-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID

Nonalcoholic Steatohepatitis

Bristol-Myers SquibbSmall moleculePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

131 Active assets in the Nonalcoholic Steatohepatitis cohort.

Asset / SponsorPhaseRating
Resmetirom
City University of New York
Phase 4BBB
Pentoxifylline
Al-Azhar University
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Semaglutide
Cascade Pharmaceuticals, Inc
Phase 4BBB
Firsocostat
Gilead Sciences
Phase 2BBB

View all 50 →

Same molecule, other indications

(1R,3S,4R)-4-((3AR,9BR)-9B-((4-FLUOROPHENYL)SULFONYL)-7-(PERFLUOROPROPAN-2-YL)-2,3,3A,4,5,9B-HEXAHYDRO-1H-BENZO(E)INDOLE-3-CARBONYL)-3-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID is also rated in:

rheumatoid arthritisDormant
CCC
Indicative ·
48 / 100
View asset →
ankylosing spondylitisDormant
CCC
Indicative ·
48 / 100
View asset →
inflammatory bowel diseaseDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →